SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-145361
Filing Date
2022-05-10
Accepted
2022-05-09 21:56:04
Documents
15
Period of Report
2022-05-09
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d335800d8k.htm   iXBRL 8-K 29030
2 EX-1.1 d335800dex11.htm EX-1.1 163057
3 EX-5.1 d335800dex51.htm EX-5.1 8491
7 GRAPHIC g335800snap1.jpg GRAPHIC 3539
  Complete submission text file 0001193125-22-145361.txt   379246

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA fulc-20220509.xsd EX-101.SCH 2863
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE fulc-20220509_lab.xml EX-101.LAB 17979
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fulc-20220509_pre.xml EX-101.PRE 11263
9 EXTRACTED XBRL INSTANCE DOCUMENT d335800d8k_htm.xml XML 3349
Mailing Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139
Business Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139 617-651-8851
Fulcrum Therapeutics, Inc. (Filer) CIK: 0001680581 (see all company filings)

IRS No.: 474839948 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38978 | Film No.: 22907141
SIC: 2834 Pharmaceutical Preparations